{
    "2019-11-28": [
        [
            {
                "time": "2018-11-28",
                "original_text": "格隆汇港股聚焦(11.28)︱波司登中期纯利上升36.4%至3.43亿元 复星医药在研白血病新药获美国孤儿药认定",
                "features": {
                    "keywords": [
                        "波司登",
                        "中期纯利",
                        "复星医药",
                        "白血病新药",
                        "孤儿药认定"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "服装"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-28",
                "original_text": "复星医药(02196)：FN-1501治疗急性髓性白血病获美国FDA孤儿药认定",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FN-1501",
                        "急性髓性白血病",
                        "FDA",
                        "孤儿药认定"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-28",
                "original_text": "复星医药(600196.SH)：白血病新药FN-1501获美国FDA孤儿药认定",
                "features": {
                    "keywords": [
                        "复星医药",
                        "白血病新药",
                        "FN-1501",
                        "FDA",
                        "孤儿药认定"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-27",
                "original_text": "智通港股通持股分析|11月27日",
                "features": {
                    "keywords": [
                        "智通港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}